Black Diamond Therapeutics Inc
BDTX
NASDAQ
Biotechnology
$2.02
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $116.92M
Volume 330.3K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-42.55M
TTM
-394.7%
YoY
Operating Cash Flow
$-32.84M
TTM
-283.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.1 | 3.5 | 4.0 | 4.3 | 4.7 |
Other Operating Expenses | 0.0 | 0.0 | 7.3 | 0.0 | 0.0 |
Total Operating Expenses | 13.4 | 11.0 | 17.6 | 11.3 | 12.1 |
Operating Income | -13.4 | -11.0 | -17.6 | -11.3 | -12.1 |
EBITDA | -13.3 | -10.9 | -10.2 | -11.2 | -12.0 |
Other Income / Expense | 1.7 | 1.3 | 1.3 | 1.2 | 1.2 |
Total Other Income / Expense | 2.9 | 2.5 | 2.5 | 2.2 | 2.2 |
Income Before Income Taxes | -10.6 | -8.5 | -15.1 | -9.0 | -9.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -10.6 | -8.5 | -15.1 | -9.0 | -9.9 |
Consolidated Net Income / Loss | -10.6 | -8.5 | -15.1 | -9.0 | -9.9 |
Net Income Attributable to Common Shareholders | -10.6 | -8.5 | -15.1 | -9.0 | -9.9 |
Basic EPS | -$0.19 | -$0.15 | -$0.26 | -$0.16 | -$0.17 |
Diluted EPS | -$0.19 | -$0.15 | -$0.26 | -$0.16 | -$0.17 |
Basic Shares Outstanding | 56.8M | 56.9M | 57.1M | 57.2M | 57.4M |
Diluted Shares Outstanding | 56.8M | 56.9M | 58.8M | 57.2M | 57.4M |